MiCo BioMed Co., Ltd. provides on-site diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) System, a device which include, membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real-time PCR system; PCR and sample prep kits; and LabChip, sample tube, and pre-filtering column. It also provides biological chemistry products, including VERI-Q Multi, a cholesterol diagnostic product; VERI-Q Hb Mate and VERI-Q RED, a hemoglobin monitoring system; and VERI-Q PRO, a blood glucose monitoring system. In addition, the company offers immunodiagnostics products, including VERI-Q COVID-19 Ag Rapid Test and VERI-Q COVID-19 IgGIgM Rapid Test for COVID testing; VERI-Q PinoView, a device for detecting markers of specific diseases through antigen-antibody reaction; and Opti96 ELISA plate/Kit. The company was formerly known as MiCo NanoBioSys Co., Ltd. and changed its name to MiCo BioMed Co., Ltd. in March 2018. MiCo BioMed Co., Ltd. was founded in 2009 and is headquartered in Seongnam-si, South Korea.
Metrics to compare | 214610 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship214610PeersSector | |
---|---|---|---|---|
P/E Ratio | −2.5x | −3.4x | −0.6x | |
PEG Ratio | −0.05 | 0.00 | 0.00 | |
Price/Book | 3.2x | 1.9x | 2.6x | |
Price / LTM Sales | 9.8x | 4.1x | 3.1x | |
Upside (Analyst Target) | - | −15.6% | 55.7% | |
Fair Value Upside | Unlock | 12.5% | 6.9% | Unlock |